vials of tirzepatide Zepbound® - Injectable hormone GLP Lilly Releases Zepbound (Tirzepatide) Single-dose

Regarding the cellular localization of GLP-1R in the CNS, there are controversial findings

People who begin at a lower BMI often reach a plateau sooner, while those with higher BMIs may continue losing weight for longer

While this represents an investment, the longevity and comprehensive improvement make it cost-competitive with repeated traditional filler treatments

Industry 3 min read Wegovy, Ozempic linked with sight-threatening eye disorder in study After taking patients' other risk factors for the condition into account, such as high blood pressure and obstructive sleep apnea, use of semaglutide was associated with a more than four times higher risk of NAION in those receiving it for diabetes and a more than seven times higher risk in patients taking it for obesity

From Phase 3 obesity contenders and oral GLP-1 breakthroughs to reframing liver and brain risk, this week reinforces a clear shift: metabolic disease care is becoming broader, earlier, and far more integrated